{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T23:40:53Z","timestamp":1791330053315,"version":"4.3.1"},"reference-count":44,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T00:00:00Z","timestamp":1643846400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>The dynamic of HIV-viral load (VL) remains poorly investigated in HIV\/HCV patients under direct acting antivirals (DAAs).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>We retrospectively evaluated HIV-VL at baseline (BL) during and up to 24 weeks post-DAAs in a cohort of 305 HIV-1\/HCV patients, on ART and with no HIV virological failure (VF) in the 6 months before treatment with DAAs; during the period of observation VF was defined as confirmed VL\u226550 copies\/mL; virological blips (VB, transient, not confirmed, VL \u226550 copies\/mL). Stepwise Cox regression models were fitted to estimate adjusted hazard ratios (aHR) of VF.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>Fifteen VF occurred in 13 patients over 187 person-years of follow-up (PYFU): incidence rate (IR) of 8.0 per 100-PYFU (95% CI = 4.0\u201312.1); 29 VBs were detected in 26 patients over 184 PYFU: IR = 15.8 per 100-PYFU (95% CI = 10.0\u201321.5). The most prominent factor associated with VF was the presence of BL HIV residual viremia (RV = HIV-RNA detectable but not precisely quantifiable) [aHR = 12.26 (95% CI = 3.74\u201340.17), P&lt;0.0001]. Other factors were \u22651 VBs in the 6 months before DAAs [aHR = 6.95 (95% CI = 1.77\u201327.37) P = 0.006] number of ART regimens failed before DAAs initiation [aHR (per more regimen) = 1.22 (95% CI = 1.04\u20131.42), P = 0.012] and age [aHR (per year older) = 1.16 (95% CI = 1.04\u20131.29), P = 0.010].<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Our findings underline the importance for close monitoring HIV-VL in selected patients. Whether this phenomenon is triggered by the rapid clearance of HCV remains to be established.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0262917","type":"journal-article","created":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T18:43:57Z","timestamp":1643913837000},"page":"e0262917","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4891-5376","authenticated-orcid":true,"given":"Giulia","family":"Morsica","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuela","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Castagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Bagaglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Salpietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Della Torre","family":"Liviana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caterina","family":"Uberti-Foppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid","family":"Hasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,2,3]]},"reference":[{"key":"pone.0262917.ref001","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S1473-3099(15)00485-5","article-title":"Prevalence and burden of HCV co-infection in people living with HIV: a global systematic review and meta-analysis","volume":"16","author":"L Platt","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"pone.0262917.ref002","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/lt.20424","article-title":"Management of hepatitis C virus infection in the setting of liver transplantation","volume":"11","author":"H Rodriguez\u2013Luna","year":"2005","journal-title":"Liver Transpl"},{"key":"pone.0262917.ref003","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1097\/QAD.0b013e32830e6d51","article-title":"Natural history of hepatitis C virus infection in HIV-infected individuals and the impact of HIV in the era of highly active antiretroviral therapy: a meta-analysis","volume":"22","author":"HH Thein","year":"2008","journal-title":"AIDS"},{"key":"pone.0262917.ref004","first-page":"369","article-title":"Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study","volume":"160","author":"V Lo Re","year":"2014","journal-title":"Ann Intern Med"},{"key":"pone.0262917.ref005","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/hiv.12357","article-title":"Systemic inflammation and liver damage in HIV\/hepatitis C virus","volume":"17","author":"KV Shmagel","year":"2016","journal-title":"HIV Med"},{"key":"pone.0262917.ref006","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1097\/QAD.0000000000001787","article-title":"Elevated liver stiffness is linked to increased biomarkers of inflammation and immune activation in HIV\/hepatitis C virus-coinfected patients","volume":"32","author":"GESIDA 3603b Study Group","year":"2018","journal-title":"AIDS"},{"key":"pone.0262917.ref007","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1097\/QAD.0000000000001203","article-title":"Virologic and immunologic aspects of HIV-hepatitis C virus coinfection","volume":"30","author":"KW Chew","year":"2016","journal-title":"AIDS"},{"key":"pone.0262917.ref008","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1089\/aid.2014.0060","article-title":"Rate and determinants of residual viremia in multidrug-experienced patients successfully treated with raltegravir-based regimens","volume":"31","author":"S Baroncelli","year":"2015","journal-title":"AIDS Res Hum Retroviruses"},{"key":"pone.0262917.ref009","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/hiv.12041","article-title":"An undetectable polymerase chain reaction signal in routine HIV plasma viral load monitoring is associated with better virological outcomes in patients receiving highly active antiretroviral therapy","volume":"14","author":"Dat AIDS Study Group","year":"2013","journal-title":"HIV Med"},{"key":"pone.0262917.ref010","doi-asserted-by":"crossref","first-page":"e319","DOI":"10.1016\/S2352-3018(15)00114-9","article-title":"Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE COINFECTION): a non-randomised, open-label trial","volume":"2","author":"JK Rockstroh","year":"2015","journal-title":"Lancet HIV"},{"key":"pone.0262917.ref011","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa1501315","article-title":"Ledipasvir and Sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"ION-4 Investigators","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0262917.ref012","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/S0140-6736(14)62483-1","article-title":"Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV(PHOTON-2): a multicenter, open-label, non-randomised, phase 3 study","volume":"385","author":"JM Molina","year":"2015","journal-title":"The Lancet"},{"key":"pone.0262917.ref013","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1093\/cid\/cix260","article-title":"Sofosbuvir and velpatasvir for the treatment of HCV in patients infected with HIV-1: an openlabel, phase 3 study","volume":"65","author":"ASTRAL-5 Investigators","year":"2017","journal-title":"Clin Infect Dis"},{"key":"pone.0262917.ref014","doi-asserted-by":"crossref","first-page":"ofx062","DOI":"10.1093\/ofid\/ofx062","article-title":"Highly successful hepatitis C virus (HCV) treatment outcomes in human immunodeficiency virus\/HCV-coinfected patients at a large, urban, Ryan white clinic","volume":"4","author":"M Patel","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"pone.0262917.ref015","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3851\/IMP3108","article-title":"Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease","volume":"22","author":"JK Rockstroh","year":"2017","journal-title":"Antivir Ther"},{"key":"pone.0262917.ref016","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/hiv.12429","article-title":"Direct-acting antivirals in hepatitisC virus (HCV)-infected and HCV\/HIV-coinfected patients: real-life safety and efficacy","volume":"18","author":"L Milazzo","year":"2017","journal-title":"HIV Med"},{"key":"pone.0262917.ref017","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1001\/jama.2015.1328","article-title":"Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial","volume":"313","author":"MS Sulkowski","year":"2015","journal-title":"JAMA"},{"key":"pone.0262917.ref018","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1056\/NEJMoa1503153","article-title":"Daclatasvir plus sofosbuvir for HCV in patients coinfected with HIV-1","volume":"373","author":"ALLY-2 Investigators","year":"2015","journal-title":"N Engl J Med"},{"key":"pone.0262917.ref019","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1002\/hep.29308","article-title":"High hepatitis C cure rates among black and nonblack human immunodeficiency virus-infected adults in an urban center","volume":"66","author":"O Falade-Nwulia","year":"2017","journal-title":"Hepatology"},{"key":"pone.0262917.ref020","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/QAI.0000000000001342","article-title":"Real-World Efficacy of Daclatasvir and Sofosbuvir, With and Without Ribavirin, in HIV\/HCV Coinfected Patients With Advanced Liver Disease in a French Early Access Cohort","volume":"75","author":"K Lacombe","year":"2017","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0262917.ref021","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.ijantimicag.2018.07.001","article-title":"Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies\/mL according to type of first-line antiretroviral regimen","volume":"52","author":"N Gianotti","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"pone.0262917.ref022","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1093\/cid\/ciq199","article-title":"HIV mono-infection is associated with FIB-4 \u2013A noninvasive Index of liver fibrosis in women","volume":"52","author":"JT Blackard","year":"2011","journal-title":"Clin Infect Dis"},{"key":"pone.0262917.ref023","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1086\/649922","article-title":"Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis B or C virus co-infection","volume":"50","author":"H Kovari","year":"2010","journal-title":"Clin Infect Dis"},{"key":"pone.0262917.ref024","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1097\/QAD.0b013e3283455e4b","article-title":"Antiretroviral treatment interruption leads to progression of liver fibrosis in HIV-hepatitis C virus co-infection","volume":"25","author":"Canadian Co-infection Cohort Study (CTN222)","year":"2011","journal-title":"AIDS"},{"key":"pone.0262917.ref025","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/hiv.12168","article-title":"HIV virological rebounds but not blips predict liver fibrosis progression in antiretroviral-treated HIV\/hepatitis C virus-coinfected patients","volume":"16","author":"Canadian Co-infection Cohort Study Investigators","year":"2015","journal-title":"HIV Med"},{"key":"pone.0262917.ref026","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.jcv.2019.04.009","article-title":"Is the rate of virological failure to cART continuing to decline in recent calendar years?","volume":"116","author":"Icona Foundation Study Group","year":"2019","journal-title":"J Clin Virol"},{"key":"pone.0262917.ref027","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1097\/QAD.0000000000000544","article-title":"Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients","volume":"29","author":"Antiretroviral Therapy Cohort Collaboration (ART-CC)","year":"2015","journal-title":"AIDS"},{"key":"pone.0262917.ref028","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/hiv.12413","article-title":"Very low level viraemia and risk of virological failure in treated HIV-1-infected patients","volume":"18","author":"VACH Study Group","year":"2017","journal-title":"HIV Med"},{"key":"pone.0262917.ref029","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1089\/apc.2014.0165","article-title":"Comparison of HIV virologic failure rates between patients with variable adherence to three antiretroviral regimen types","volume":"29","author":"LL Gordon","year":"2015","journal-title":"AIDS Patient Care STDS"},{"key":"pone.0262917.ref030","doi-asserted-by":"crossref","first-page":"e3361","DOI":"10.1097\/MD.0000000000003361","article-title":"Adherence to antiretroviral therapy and virologic failure: a meta-analysis","volume":"95","author":"WM Bezabhe","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"pone.0262917.ref031","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1517\/17425255.2015.996546","article-title":"Drug-drug interactions between anti-retroviral therapies and drugs of abuse in HIV systems","volume":"11","author":"S Kumar","year":"2015","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"pone.0262917.ref032","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1002\/jmv.24017","article-title":"The role of baseline HIV-1 RNA, drug resistance, and regimen type as determinants of response to first-line antiretroviral therapy","volume":"86","author":"ARCA Collaborative Group","year":"2014","journal-title":"J Med Virol"},{"key":"pone.0262917.ref033","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/S1473-3099(11)70032-9","article-title":"Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study","volume":"11","author":"EuroCoord-CHAIN study group","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"pone.0262917.ref034","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/QAI.0000000000000942","article-title":"Response to therapy in antiretroviral therapy-naive patients with isolated nonnucleoside reverse transcriptase inhibitor-associated transmitted drug resistance","volume":"72","author":"DS Clutter","year":"2016","journal-title":"J Acquir Immune Defic Syndr"},{"key":"pone.0262917.ref035","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/QAD.0000000000000903","article-title":"Effect of HIV co-infection on adherence to a 12-week regimen of hepatitis C virus therapy with ledipasvir and sofosbuvir","volume":"30","author":"K Townsend","year":"2016","journal-title":"AIDS"},{"key":"pone.0262917.ref036","doi-asserted-by":"crossref","first-page":"ofz318","DOI":"10.1093\/ofid\/ofz318","article-title":"Evaluation of safety and effectiveness of elvitegravir\/cobicistat\/ emtricitabine tenofovir alafenamide switch followed by ledipasvir\/sofosbuvir HCV therapy in HIV\u2013HCV coinfection","volume":"6","author":"MA Doyle","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"pone.0262917.ref037","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/S2468-1253(18)30002-5","article-title":"Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis","volume":"3","author":"MM M\u00fccke","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"pone.0262917.ref038","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1002\/hep.22951","article-title":"Hepatitis B and C virus coinfection: a novel model system reveals the absence of direct viral interference","volume":"50","author":"P Bellecave","year":"2009","journal-title":"Hepatology"},{"key":"pone.0262917.ref039","first-page":"8ofab079","article-title":"T-cell activation is correlated with monocyte activation in HCV\/HIV coinfection and declines during HCV direct-acting antiviral therapy","author":"AWN Auma","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"pone.0262917.ref040","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1093\/infdis\/jir353","article-title":"Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during first-line therapy","volume":"204","author":"B Taiwo","year":"2011","journal-title":"J Infect Dis"},{"key":"pone.0262917.ref041","doi-asserted-by":"crossref","first-page":"e36673","DOI":"10.1371\/journal.pone.0036673","article-title":"Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patients","volume":"7","author":"C Delaugerre","year":"2012","journal-title":"PLoS One"},{"key":"pone.0262917.ref042","doi-asserted-by":"crossref","first-page":"5998","DOI":"10.1128\/AAC.01217-12","article-title":"Prevalence and significance of HIV-1 drug resistance mutationsamong patients on antiretroviral therapy with detectable low-level viremia","volume":"56","author":"JZ Li","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"pone.0262917.ref043","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00430-017-0518-x","article-title":"Time course of cellular HIV-DNA and low-level HIV viremia in HIV-HCV co-infected patients whose HCV infection had been successfully treated with directly acting antivirals","volume":"206","author":"SG Parisi","year":"2017","journal-title":"Med Microbiol Immunol"},{"key":"pone.0262917.ref044","doi-asserted-by":"crossref","first-page":"e0187095","DOI":"10.1371\/journal.pone.0187095","article-title":"Peripheral blood HIV-1 DNA dynamics in antiretroviral-treated HIV\/HCV co-infected patients receiving directly-acting antivirals","volume":"12","author":"G Rozera","year":"2017","journal-title":"PLoS One"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,3]],"date-time":"2022-02-03T18:44:42Z","timestamp":1643913882000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0262917"}},"subtitle":[],"editor":[{"given":"Chen-Hua","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,2,3]]},"references-count":44,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,2,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0262917","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,3]]}}}